Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged pipeline milestones led by encouraging lung‑cancer data for lifileucel. 1

• Q3 revenue ~$68M, up ~13% QoQ; gross margin 43%. The company cited improved execution and early benefits of cost optimization. Full‑year 2025 revenue guidance remains $250–$300M in Amtagvi’s first full calendar year on the market. 1
• Bottom line: Net loss of $91.3M (‑$0.25 per share). Revenue of $67.5M missed consensus, while EPS beat some estimates, according to Associated Press/Zacks summaries. 2
• Regulatory & pipeline: Interim IOV‑LUN‑202 data in nonsquamous NSCLC show an ~26% ORR with median duration of response not reached (>25 months), supporting plans to pursue regulatory pathways; more data are expected in 2026. 3
• Operations & access: >80 U.S. authorized treatment centers now active; distribution broadened via a specialty‑pharmacy agreement with InspiroGene by McKesson; average manufacturing turnaround ~32 days. 1
• Liquidity: Cash, equivalents, investments, and restricted cash ~$307M at Sept. 30; runway expected into Q2 2027 after recent cost actions. 1
• Compliance note: Iovance furnished its results and press release via an SEC Form 8‑K this morning. 4

What Iovance announced (Nov. 6, 2025)

Revenue, margin, and guidance. Total product revenue grew to ~$68M in Q3 (Amtagvi ~$58M; Proleukin ~$10M). Gross margin expanded to 43% on improved execution and early cost‑savings. Management reaffirmed $250–$300M in 2025 revenue. 1

Earnings snapshot. An AP/Automated Insights brief noted a net loss of $91.3M or ‑$0.25 per share on $67.5M in revenue, with EPS topping some forecasts but sales below Street expectations. 2

Filing & webcast. The company filed an 8‑K with the press release and scheduled a conference call and webcast at 8:30 a.m. ET to review results and provide updates. 4

Investor materials. Iovance also posted a fresh corporate presentation dated today, aligning with the Q3 update. 5

Commercial execution: where growth is coming from

• Treatment‑center footprint. Iovance says >80 U.S. authorized treatment centers (ATCs) are active across nearly 40 states, placing ~95% of eligible patients within a ~two‑hour drive. Expansion into community centers is expected to support earlier treatment and demand. 1
• Patient access & logistics. A new specialty‑pharmacy agreement with InspiroGene by McKesson is intended to broaden access. Meanwhile, manufacturing turnaround averages ~32 days from inbound tumor sample to shipment back to ATCs, with further operational initiatives underway. 1
• Global expansion.Health Canada approved Amtagvi in August 2025; Iovance anticipates potential approvals in the U.K. and Australia in 1H26 and in Switzerland in 2027, and is finalizing an EMA strategy. 1

Pipeline update: lifileucel beyond melanoma

• NSCLC (IOV‑LUN‑202). Interim Phase 2 monotherapy data in previously treated nonsquamous NSCLC reported an ~26% objective response rate with median DOR not reached after >25 months. The design has positive FDA feedback, and Iovance expects enrollment completion in 2026, targeting a supplemental BLA and a potential 2027 launch if successful. 3
• Broader development. Early readouts for endometrial cancer (IOV‑END‑201) are planned for early 2026; the TILVANCE‑301 combo trial (lifileucel + pembrolizumab) continues in frontline melanoma; next‑gen programs IOV‑4001 (PD‑1–inactivated TIL), IOV‑3001 (next‑gen IL‑2), and IOV‑5001 (inducible tethered IL‑12 TIL) are slated for updates through 2026. 1

By the numbers (Q3 2025)

• Revenue: ~$68M (Amtagvi ~$58M; Proleukin ~$10M) — up ~13% QoQ. 1
• Gross margin:43% (improved execution/cost optimization). 1
• Net loss / EPS:‑$91.3M / ‑$0.25; revenue $67.5M vs. lower‑Street consensus in AP brief. 2
• Cash & investments:~$307M (runway into Q2 2027). 1

Market reaction (intraday)

As of publication time, IOVA shares were trading around $2.16 intraday, with the session range between $1.76–$2.41 (time stamp ~14:42 UTC). See live chart above.

What to watch next

1. Commercial ramp cadence. Watch activation and throughput at community ATCs, the InspiroGene distribution channel, and any additional real‑world data disclosures that might influence adoption curves. 1
2. Manufacturing consolidation. The plan to centralize manufacturing at the Iovance Cell Therapy Center (iCTC) in early 2026 could be a margin lever; execution will matter. 1
3. Ex‑U.S. milestones. Decisions or filings in the U.K., Australia (1H26), and Switzerland (2027), plus progress on the EMA path. 1
4. NSCLC readouts. Additional IOV‑LUN‑202 data (planned 2026) and regulatory interactions that may set the pace toward a 2027 launch. 3

Source notes (Nov. 6, 2025)

• Company press release summarizing Q3 results, operations, and pipeline; webcast details and guidance. 1
• SEC Form 8‑K furnishing the Q3 press release. 4
• AP/Automated Insights earnings snapshot syndicated via Hearst (Times Union). 2
• Quiver Quantitative note on consensus beats/misses. 6
• Corporate presentation posted today (MarketScreener/PublicNow). 5
• Nov. 3 Iovance press release and independent coverage on IOV‑LUN‑202 interim data in NSCLC. 3

Editor’s note: This article is for informational purposes only and does not constitute investment advice.